title: The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme.
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: S
authors: S
authors: Kurklinsky
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: S O
authors: SO
authors: Abdul-Hay
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: M P
authors: MP
authors: McGuire
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: E A
authors: EA
authors: Howard
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: J
authors: J
authors: Knight
authors: Department of Neuroscience, Mayo Clinic, Jacksonville, USA.
authors: M A
authors: MA
authors: Leissring
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology*; D007339:Insulysin / Q000037:antagonists & inhibitors*; D008297:Male; D015244:Thiorphan / Q000031:analogs & derivatives*
chemical_list: D015244:Thiorphan; D007339:Insulysin
references: J Med Chem. 2013 Mar 28;56(6):2246-55
references: 23437776
references: Diabetes. 1986 Jun;35(6):675-83
references: 3519322
references: Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9582-7
references: 18621727
references: Horm Metab Res. 2011 Jun;43(7):489-93
references: 21557151
references: PLoS One. 2009;4(4):e5274
references: 19384407
references: J Mol Biol. 1999 Sep 10;292(1):11-7
references: 10493853
references: PLoS One. 2010 May 07;5(5):e10504
references: 20498699